EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Low‐Dose Oral Versus Topical Minoxidil in Androgenetic Alopecia: A Randomized, Double‐Blind, Double‐Dummy Controlled Trial

Muhammad Asad Ejaz Chaudhry, Bushra Muneeb, Safoora Aamir, Zoha Arif Saeed, Sidra Ashraf, Shoaib Ashraf

Journal of Cosmetic Dermatology · 2026-10 · 25 (10)

DOI: 10.1111/jocd.71198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 21.09.2026. Verfasst von Muhammad Asad Ejaz Chaudhry und 5 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Androgenetic alopecia (AGA) is a prevalent, progressive condition with significant psychosocial impact. Current pharmacological modalities like topical minoxidil and finasteride have limitations. Low‐dose oral minoxidil has surfaced as a valid off‐label solution, with the practical advantage of once‐daily dosing.

Objective

To evaluate the efficacy and safety of topical and oral minoxidil in AGA.

Methods

In this double‐blind, double‐dummy randomized controlled trial, 100 patients aged 18–50 years with AGA were randomized to receive either twice‐daily topical minoxidil (5% in males, 2% in females) plus a placebo tablet, or once‐daily oral minoxidil (2.5 mg in males, 1.25 mg in females) plus a placebo spray for 6 months. The primary outcome was the proportion of patients achieving ≥ +1 improvement in a validated 7‐point global photographic scale. Secondary outcomes included patient satisfaction and adverse effects. Data were analyzed using SPSS v26 with p ≤ 0.05 as significant.

Results

Ninety patients completed 24 weeks of follow‐up. Photographic assessment demonstrated that mild‐to‐excellent improvement (≥ +1) occurred in both the oral (67%) and topical minoxidil (73%) groups ( p = 0.652). Patient‐reported satisfaction was high in both groups (topical: 70.5%; oral: 80.4%, p = 0.332), with a non‐significant trend favoring oral minoxidil at the moderate satisfaction threshold (58.7% vs. 38.6%, p = 0.057). Median improvement scores were comparable between groups for both clinician assessment and patient‐reported outcomes. Hypertrichosis was significantly more frequent with oral minoxidil (30% vs. 9%, p = 0.011), whereas contact dermatitis was exclusive to topical minoxidil (11% vs. 0%, p = 0.025). No serious adverse events were observed.

Conclusion

Both topical and low‐dose oral minoxidil demonstrated clinically meaningful improvement in androgenetic alopecia. Despite oral therapy exhibiting a trend toward higher patient satisfaction, this study was not powered to establish non‐inferiority or equivalence. The dermatologist‐assessed outcomes indicated no significant intergroup differences. Low‐dose oral minoxidil may be considered a practical alternative in selected patients, particularly where adherence to topical therapy is limited. Trial Registration ClinicalTrials.gov : NCT07273799

Zitieren

APA

Chaudhry, M. A. E., Muneeb, B., Aamir, S., Saeed, Z. A., Ashraf, S., & Ashraf, S. (2026). Low‐Dose Oral Versus Topical Minoxidil in Androgenetic Alopecia: A Randomized, Double‐Blind, Double‐Dummy Controlled Trial. Journal of Cosmetic Dermatology, 25(10). https://doi.org/10.1111/jocd.71198

Vancouver

Chaudhry MAE, Muneeb B, Aamir S, Saeed ZA, Ashraf S, Ashraf S. Low‐Dose Oral Versus Topical Minoxidil in Androgenetic Alopecia: A Randomized, Double‐Blind, Double‐Dummy Controlled Trial. Journal of Cosmetic Dermatology. 2026;25(10). doi:10.1111/jocd.71198

BibTeX
@article{Chaudhry2026,
  author = {Chaudhry, Muhammad Asad Ejaz and Muneeb, Bushra and Aamir, Safoora and Saeed, Zoha Arif and Ashraf, Sidra and Ashraf, Shoaib},
  title = {Low‐Dose Oral Versus Topical Minoxidil in Androgenetic Alopecia: A Randomized, Double‐Blind, Double‐Dummy Controlled Trial},
  journal = {Journal of Cosmetic Dermatology},
  year = {2026},
  volume = {25},
  number = {10},
  doi = {10.1111/jocd.71198}
}
Kostenlos starten →